Chicago—Busulfan and melphalan in combination (BuMel) may represent a potential new standard treatment for high-risk, localized Ewing sarcoma according to the results of a Phase III trial. In the trial, significant improvements in event-free (EFS) and overall survival (OS) were achieved with BuMel compared with vincristine, actinomycin D and ifosfamide (VAI).
In an intention-to-treat analysis, the primary outcome of EFS rose from 53% among patients treated with VAI to 67% among those